Trial Profile
A phase I study of weekly nab-Paclitaxel/Carboplatin with concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Sep 2021 Results published in the Investigational New Drugs
- 09 Aug 2019 Status changed from recruiting to active, no longer recruiting.